New Phase 3 trial: RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
🇺🇸 ClinicalTrials.gov · Fri 13 Nov 2026
RemeGen Co., Ltd.. Condition: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Intervention: RC118(Dose 1) plus RC148(Dose 1), RC118(Dose 1) plus RC148(Dose 2), RC118(Dose 2) plus RC148(Dose 1). NCT07935369.
ClinicalTrials.gov record: ClinicalTrials.gov ↗
Brief written by VigiEye from the company's press release. Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Clinical trialsCompany releaseCalidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
🇺🇸 Calidi Biotherapeutics, Inc. (CLDI) · Fri 13 Nov 2026
Clinical trialsCompany releaseIRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
🇺🇸 IRulya Therapeutics Inc. (IRLA) · Fri 13 Nov 2026
Clinical trialsCompany releaseMacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
🇺🇸 Macrogenics Inc (MGNX) · Fri 13 Nov 2026
Clinical trialsCompany releaseCerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
🇺🇸 Cerenome, Inc. (CNSY) · Fri 13 Nov 2026
Clinical trialsCompany releaseCuris reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
🇺🇸 Curis Inc (CRIS) · Fri 13 Nov 2026
Clinical trialsCompany releaseBluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027
🇺🇸 Bluejay Diagnostics, Inc. (BJDX) · Fri 13 Nov 2026